In Australia, occupational Asthma is managed by occupational medicines. Occupational asthma is adult-onset asthma caused or made worse by exposures at work, and it is the most common occupational lung disease in industrialized countries, accounting for an estimated 9-15% of all adult-onset asthma. Workers in healthcare, baking, woodworking, spray painting, cleaning, hairdressing, and agriculture are most affected; more than 400 high-molecular-weight (flour, animal proteins, latex) and low-molecular-weight (isocyanates, persulfates, glutaraldehyde, metal salts) sensitizing agents are documented.
Occupational asthma (ICD-10: J45.0 in extrinsic asthma with sensitizing agent) is asthma caused or aggravated by exposure to agents encountered in the workplace. The American Thoracic Society and European Respiratory Society jointly classify it into two main forms: sensitizer-induced occupational asthma (allergic, immunologically mediated, latency period from months to years between first exposure and symptom onset) and irritant-induced occupational asthma (non-allergic, includes the classic reactive airways dysfunction syndrome (RADS) following a high-level acute exposure, and the related entity of low-dose irritant-induced asthma after repeated lower-level exposures). Sensitizer-induced disease accounts for roughly 90% of cases and is further divided by molecular size: high-molecular-weight agents (flour, animal dander, latex, enzymes) work through classical IgE-mediated mechanisms with positive skin-prick tests and specific IgE; low-molecular-weight agents (isocyanates, persulfates, anhydrides, metal salts, cleaning chemicals) often work through specific IgE plus T-cell-mediated mechanisms and may not be detectable on standard skin testing. A separate but related entity, work-exacerbated asthma, describes pre-existing asthma worsened by workplace irritants without development of new sensitization.
The key symptoms of Occupational Asthma are: Cough, wheeze, chest tightness, and shortness of breath that begin or worsen during work shifts and improve on weekends or holidays — the most useful diagnostic pattern (sensitivity 60-80%)., Symptoms typically appearing several hours into a shift or in the evening after work; some patients have nocturnal symptoms peaking 8-12 hours after the workplace exposure (late asthmatic response)., Rhinoconjunctivitis (sneezing, nasal congestion, itchy red eyes) that precedes or accompanies asthma symptoms in 70-90% of patients with high-molecular-weight sensitizer-induced disease., Urticaria, eczema flare, or angioedema on exposed skin (face, hands, neck) suggesting concurrent dermal sensitization., Exercise tolerance reduced during work weeks and recovered during periods away from work., Progressive worsening of symptoms over months despite symptomatic asthma treatment when exposure continues., Acute severe bronchospasm shortly after high-level irritant exposure (chlorine spill, fume release, smoke inhalation) — RADS presentation..
Diagnosis follows a structured stepwise approach codified in the ATS/ERS 2014 statement and similar national guidelines. Step 1 is to confirm asthma in the patient (variable airflow obstruction on spirometry with bronchodilator reversibility, or methacholine challenge with PC20 below 8 mg/mL when baseline FEV1 is normal). Step 2 is to establish a work-related pattern: a detailed occupational history capturing job tasks, exposures, latency, and a symptom pattern that worsens at work and improves away from work. Step 3 is to objectively document the work relationship: serial peak expiratory flow (PEF) measurements every 2 hours at and away from work for at least 4 weeks (2 at work and 2 away) showing greater diurnal variability or worse mean during work weeks. The Oasys software analyzes such PEF records and provides a validated work-effect score (specificity above 90% when the score is in the 'consistent' range). Step 4 identifies the specific sensitizer where possible: skin-prick tests and serum specific IgE for high-molecular-weight allergens (flour, animal dander, latex) and selected low-molecular-weight agents (isocyanates) are commercially available. Step 5, where feasible, is a specific inhalation challenge (SIC) in a specialized laboratory — the diagnostic gold standard. SIC exposes the patient to controlled doses of the suspected agent and measures FEV1 response; a fall of 20% or more confirms diagnosis. Fractional exhaled nitric oxide (FeNO) measurement, sputum eosinophil counts, and methacholine challenge before and after exposure provide additional support. Imaging is generally normal in occupational asthma; chest CT excludes alternative diagnoses such as hypersensitivity pneumonitis.
Outcome depends critically on time to diagnosis and exposure removal. Workers diagnosed and fully removed within 12 months of symptom onset achieve asthma remission in 30-50%; those removed within 24 months in 20-40%; beyond 24 months remission falls below 20%. Workers continuing exposure show progressive lung function decline (FEV1 fall of 50-100 mL per year) and develop severe persistent asthma in 60-80%. Quality of life and earning capacity are substantially affected — work loss, retraining, and disability claims are common. RADS often improves over 1-3 years but bronchial hyperresponsiveness can persist indefinitely. Severe occupational asthma with eosinophilic phenotype responds well to biologic therapy. Mortality is uncommon but possible during severe exacerbations; modern treatment has reduced asthma deaths overall. Workplace surveillance with periodic spirometry detects disease at earlier, more reversible stages.
Refer to a pulmonologist or occupational physician at first suspicion of work-related asthma. Specialist input is essential for confirming the work association with serial PEF, specific IgE, and where available specific inhalation challenge, for advising on removal from exposure, and for coordinating workplace, compensation, and medical management. Severe or persistent disease warrants tertiary referral for biologic therapy consideration.
Find specialists →Symptom improvement after exposure removal begins within 4-12 weeks. Significant lung function recovery is usually apparent by 6-12 months. Airway hyperresponsiveness (methacholine PC20) improves over 12-24 months. Remission, when achieved, becomes evident over 1-3 years. RADS symptoms typically improve over 1-3 years but residual airway hyperresponsiveness can be permanent.
Aerobic exercise — walking, swimming, cycling — for 30 minutes most days improves overall asthma control. Warm-up periods of 10-15 minutes reduce exercise-induced bronchoconstriction. Patients with exercise-induced symptoms should pre-treat with 2 puffs of ICS-formoterol or salbutamol 10-15 minutes before exercise. Avoid outdoor exercise during high pollen, high pollution, or extreme cold-air exposure. Supervised pulmonary rehabilitation is recommended for moderate-severe disease and after a major exacerbation.
Choose a pulmonologist with an occupational lung disease clinic, ideally one with access to specific inhalation challenge facilities and links to occupational medicine. Ask whether they perform serial PEF analysis, methacholine challenge, specific IgE, and biologic therapy selection. Occupational physicians are key partners and can advise on workplace controls, compensation, and return-to-work strategies.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Australia.
Apply as specialist →Specialists who treat Occupational Asthma. Get expert guidance and personalized care.